Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
Kyverna Therapeutics (Nasdaq: KYTX) announced that CEO Warner Biddle will present at the J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kyverna Therapeutics (Nasdaq: KYTX) announced that CEO Warner Biddle will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 14, 2026 at 9:45 a.m. PT.
Investors can access a live audio webcast via the company's Investors page at ir.kyvernatx.com. A replay will be available on the website for 30 days after the conference.
Details
News Market Reaction – KYTX
On Jan 5, the day this news came out, KYTX closed 7.30% below the previous close.
Data tracked by StockTitan Argus for the Jan 5 session.
Key Figures
- Conference date
- January 14, 2026
- J.P. Morgan 2026 Healthcare Conference presentation
- Presentation time
- 9:45 a.m. PT
- Scheduled J.P. Morgan conference session
- Webcast replay window
- 30 days
- Replay availability following the conference
Historical Context
-
Underwritten public offering of 13,333,333 shares at $7.50 per share.
-
Proposed $100,000,000 common stock offering with 30-day underwriter option.
-
Positive topline Phase 2 KYSA-8 data in stiff person syndrome with strong efficacy.
-
Announcement of webcast to review registrational KYSA-8 topline results.
-
Q3 2025 business update with clinical progress and strengthened financing position.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14th, 2026, at 9:45 a.m. PT.
A live audio webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications. Additionally, its next generation pipeline includes CAR T-cell therapies deploying novel innovations to improve patient access and experience. For more information, please visit https://kyvernatx.com.
Contacts:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.